Abstract Number: 0560 • ACR Convergence 2021
Effectiveness, Safety, Quality of Life and Patient Satisfaction with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: Second Interim Analysis of a German Non-Interventional, Prospective, Multi-Center Study
Background/Purpose: Tofacitinib is a Janus kinase inhibitor, which is orally applied and is approved for rheumatoid arthritis among other indications. ESCALATE-RA is the first prospective,…Abstract Number: 0584 • ACR Convergence 2021
High Number of Comorbidities and Concomitant Medications at Baseline in the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) Study: An Older Population with Rheumatoid Arthritis
Background/Purpose: Older people are often underrepresented in trials because the generally high number of comorbid conditions (1). The objective of this abstract is to document…Abstract Number: 0631 • ACR Convergence 2021
Provider Assessment of Telehealth Utility During COVID-19
Background/Purpose: The COVID-19 pandemic forced the provision of telehealth care to rheumatology patients with a broader range of diagnoses and disease activity than previously studied.…Abstract Number: 0790 • ACR Convergence 2021
Unraveling Heterogeneity Within ACPA-negative Rheumatoid Arthritis; The Subgroup of Patients with a Strong Clinical and Serological Response to Initiation of DMARD-treatment Favor Disease Resolution
Background/Purpose: Rheumatoid arthritis (RA) is a heterogeneous disease, especially ACPA-negative-RA. This is reflected by differences in long-term outcomes, ranging from refractory RA to sustained-DMARD-free-remission(SDFR; sustained…Abstract Number: 0806 • ACR Convergence 2021
Coping with Recent-onset Rheumatoid Arthritis (RA): Validation of the Coping with Health Injuries and Problems (CHIP) Questionnaire in a Longitudinal Cohort
Background/Purpose: Receiving a Rheumatoid Arthritis (RA) diagnosis presents a significant health stressor. Given that little is known about how patients cope with it, we aimed…Abstract Number: 0825 • ACR Convergence 2021
An Investigator-initiated Multicenter Randomized Study in Early Rheumatoid Arthritis of Active Conventional Therapy versus Three Biological Treatments: 48 Week Clinical and Radiographic Results of the NORD-STAR Trial
Background/Purpose: The optimal first-line treatment of patients (pts) with early rheumatoid arthritis (eRA) is yet to be established. The main objectives were to assess and…Abstract Number: 0841 • ACR Convergence 2021
Persistence on JAK Inhibitors in Daily Practice: Evaluation of the Rhadar-registry
Background/Purpose: The treatment strategy for rheumatoid arthritis (RA) includes achieving remission or at least low disease activity within six months of starting therapy. Active RA…Abstract Number: 0995 • ACR Convergence 2021
Innate Immune Tolerance Attenuates Zymosan-Induced Arthritis, Inflammatory Gene Expression and Synovial Neutrophil Infiltration
Background/Purpose: Zymosan (Zym) induces arthritis through TLR2- and Dectin-1-activated NK-κB signaling and inflammatory myeloid cell infiltration into the synovium of the injected joint. Innate immune…Abstract Number: 1074 • ACR Convergence 2021
Satisfaction with a Virtual Learning Collaborative Aimed at Implementing Treat to Target (TTT) in Rheumatoid Arthritis (RA)
Background/Purpose: Learning collaboratives (LC) have been used widely for quality improvement in healthcare, and a recent 9-month in person LC was found effective for improving…Abstract Number: 1201 • ACR Convergence 2021
Younger Age and Smoking Status Are Associated with Delayed Diagnosis of Rheumatoid Arthritis in a U.S. Veteran Population
Background/Purpose: RA is a complex multisystem disease, which, untreated, results in debilitating joint damage, excess morbidity, and premature mortality. Previous research has demonstrated an association…Abstract Number: 1217 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as the first or an alternative option to biologic disease-…Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…Abstract Number: 1249 • ACR Convergence 2021
In Rheumatoid Arthritis, Inhibition of the Lactate Monocarboxylate Transporters-1, and -4 in Pathological Fibroblast-Like Synoviocytes Led to Decreased ChemokineProduction
Background/Purpose: Pathological subsets of fibroblast-like synoviocytes (FLS) have recently been identified as key players in the aggravation of both persistent joint inflammation and destruction in…Abstract Number: 1448 • ACR Convergence 2021
Virtual Visits versus Face-to-Face Visits for Rheumatoid Arthritis (RA): Comparison of Treat to Target (TTT) Adherence in 18 US Rheumatology Practices
Background/Purpose: TTT is the recommended paradigm for managing RA according to major rheumatology organizations, however the literature suggests that TTT has not been widely implemented…Abstract Number: 1646 • ACR Convergence 2021
Abnormal Cerebrovascular Biomarkers in Patients with Rheumatoid Arthritis: Results from a Prospective Study of Cognitive Aging
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cognitive impairment compared to the general population. This association might be due to chronic…
- « Previous Page
- 1
- …
- 112
- 113
- 114
- 115
- 116
- …
- 188
- Next Page »